SABS
SABS clinical trials: SAB Biotherapeutics, Inc.
Every trial on ClinicalTrials.gov where SAB Biotherapeutics, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 9
- Trials linked
- 6
- As lead sponsor
- 3
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
SABS on the catalyst calendar · SABS registry changes
- Primary completion Nov 2027Sponsor estimatePhase 2NCT07187531SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 DiabetesSAb Biotherapeutics, Inc. · Type 1 DiabetesRecruitingSABSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 8, 2021ActualPhase 2NCT04850898Study of SAB-176 in Healthy Adult ParticipantsSAb Biotherapeutics, Inc. · Influenza A H1N1CompletedSABSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 19, 2021ActualPhase 1NCT04471038Safety, Tolerability, and Pharmacokinetics of SAB-176 in Healthy ParticipantsSAb Biotherapeutics, Inc. · Influenza Type ACompletedSABSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 1, 2025Sponsor estimatePhase 1NCT06435936A Study to Assess the Safety of SAB-176 to Prevent the Flu, Given IM in Healthy Adults Compared With PlaceboSAb Biotherapeutics, Inc. · PHA1AUnknown statusSABSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 23, 2020ActualPhase 1NCT04468958Safety, Tolerability, and Pharmacokinetics of SAB-185 in Healthy ParticipantsSAb Biotherapeutics, Inc. · COVID-19CompletedSABSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 25, 2021ActualPhase 1NCT04469179Safety, Tolerability, and Pharmacokinetics of SAB-185 in Ambulatory Participants With COVID-19SAb Biotherapeutics, Inc. · COVID-19Unknown statusSABSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 1, 2029Sponsor estimatePhase 3NCT07670650PRISE (Personalized Response and Immunologic Surveillance of Endogenous C-Peptide Preservation in New, Recent, and Established Onset...University of Florida · Type 1 Diabetes (T1D)RecruitingSABSCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 7, 2022ActualPhase 2/Phase 3NCT04518410ACTIV-2: A Study for Outpatients With COVID-19National Institute of Allergy and Infectious Diseases (NIAID) · Coronavirus
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 10, 2018ActualPhase 1NCT02788188Safety, Tolerability, and Pharmacokinetics of SAB-301 in Healthy AdultsNational Institute of Allergy and Infectious Diseases (NIAID) · Middle East Respiratory Syndrome CoronavirusCompletedSABSCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 9 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner